How does Bill Meury celebrate a $14 billion merger? With a new post at a Blackstone-founded biotech. Meury has been appointed ...

When Regeneron announced a $500 million corporate venture capital fund last week, it was the first time in years that a ...

A small German biotech attempting to crack into the gene editing field with an evolved approach to a decades-old research ...

In a study published Monday in JAMA, researchers are calling on the FDA to share more about how the agency considers the use ...

Pfizer is letting go an undisclosed number of employees and ending research operations at its site in Boulder, CO, the ...

Cardinal Health’s distribution contract with pharmacy benefit manager OptumRx will expire at the end of June and it will not ...

SynOx Therapeutics has completed a $75 million Series B raise to advance its monoclonal antibody drug through a ...

Eisai and BioArctic — the companies behind the first Alzheimer’s drug proven to slow disease progression — are inking another ...

Boehringer Ingelheim is paying Ochre Bio $35 million upfront to discover new treatments for chronic liver diseases like ...

Bios­plice’s os­teoarthri­tis drug has failed a Phase 3 clin­i­cal tri­al, ac­cord­ing to the drug­mak­er, sig­nif­i­cant­ly ...

Rube­do Life Sci­ences is fur­ther­ing its plan to treat age-re­lat­ed dis­eases by tar­get­ing senes­cent cells with a $40 ...

Corner Therapeutics' $54 million Series A will be used to bring new immunotherapies for cancer and infectious diseases into ...